U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377058) titled 'RCT of Tocilizumab for Anti-MDA5+DM' on Nov. 23, 2025.
Brief Summary: The goal of this clinical trial is to learn if tocilizumab works to treat anti-MDA5+ dermatomyositis (anti-MDA5+DM) in adults. It will also learn about the safety of tocilizumab. The main questions it aims to answer are:
Does tocilizumab improve patients' clinical symptoms? Does tocilizumab improve patients' respiratory failure? What medical problems do participants have when taking tocilizumab? Researchers will compare tocilizumab to a placebo (a look-alike substance that contains no drug) to see if tocilizumab works to treat patients with anti-MDA5+ DM.
Partic...